

**Literature Search**  
**ACR Appropriateness Criteria®**  
**Pretreatment Detection, Surveillance, and Staging of**  
**Prostate Cancer**

Literature Search Performed on: 01/29/2021

Beginning Date: January 2000

End Date: December 2020

Database: Ovid MEDLINE(R) ALL <1946 to January 28, 2021>

**Search Strategy**

---

- 1 (prostate cancer and PSA Screening).af. (1092)
- 2 exp mortality/ or mortality.af. or mortalities.af. or mortality.sh. (1331242)
- 3 1 and 2 (406)
- 4 limit 3 to randomized controlled trial (31)
- 5 ferumoxtran-10.nm,rn,rs,rx,ps,px. or ferumoxtran-10.af. or uspio.af. or uspios.af. (1158)
- 6 prostat.af. or exp prostate/ or prostate.af. or prostates.af. or prostatic.af. or exp prostatism/ or prostatism.af. or exp prostatitis/ or prostatitis.af. (256283)
- 7 5 and 6 (54)
- 8 cholin.af. or exp choline/ or choline.af. or cholines.af. or choline&#39;s.af. (88824)
- 9 (exp risk/ or risk.af.) and (intermediate or intermediated or intermediately or intermediates or high).af. (800591)
- 10 exp risk/ or risk.af. (2762844)
- 11 (stage or staged or stages or staging or stagings).af. (1265856)
- 12 prostat.af. or exp prostate/ or prostate.af. or prostates.af. or prostatic.af. or exp prostatism/ or prostatism.af. or exp prostatitis/ or prostatitis.af. (256283)
- 13 (PET or positron emission).af. (143329)
- 14 metastas\*.af. (478453)
- 15 8 and 9 and 10 and 11 and 12 and 13 and 14 (40)
- 16 ((fluciclovine or facbc) and (PET or positron emission)).af. (274)
- 17 (intermediate or intermediated or intermediately or intermediates or high).af. (4526771)
- 18 (exp risk/ or risk.af.) and (stage or staged or stages or staging or stagings).af. (197436)
- 19 metastas\*.af. (478453)
- 20 (Prostat or prostate or prostates or prostatic or prostatism or prostatitis).af. or exp prostate/ or exp prostatism/ or exp prostatitis/ (256283)
- 21 16 and 17 and 18 and 19 and 20 (8)
- 22 4 or 7 or 15 or 21 (129)
- 23 limit 22 to yr="2000 -Current" (125)

---

Literature Search Performed on: 10/19/2020

Beginning Date: January 2016

End Date: September 2020

Database: Ovid MEDLINE(R) ALL <1946 to October 16, 2020>

**Search Strategy**

---

- 1 exp diagnostic imaging/ and \*Prostatic Neoplasms/di, dg, pa and (Neoplasm grading/ or Neoplasm Staging/ or Prostate-Specific Antigen/ or prostate/ or Neoplasm Metastasis/) (5979)
- 2 Prospective Studies/ or Retrospective Studies/ or Comparative Study/ or Risk Assessment/ or Systematic Review/ (3318472)
- 3 1 and 2 (2550)
- 4 exp diagnostic imaging/ and \*Prostatic Neoplasms/ (15735)
- 5 limit 4 to (meta analysis or randomized controlled trial or practice guideline) (464)
- 6 (Biomarkers and prostate cancer and psa and (Decipher or Oncotype or Prolaris or ProMark)).tw. (8)
- 7 \*American Cancer Society/ and \*SEER Program/ and Prostate.tw. (1)
- 8 PET MRI.kw. and prostate.ti. (41)
- 9 3 or 6 or 7 or 8 (2592)

**Literature Search**  
**ACR Appropriateness Criteria®**  
**Pretreatment Detection, Surveillance, and Staging of**  
**Prostate Cancer**

10 9 and (detection or assess\$4 or diagnosis or staging or surveillance or imaging).tw. (2242)

11 5 and imaging.tw. (173)

12 10 or 11 (2361)

13 limit 12 to (abstracts and english language and yr="2016 -Current") (1001)

14 limit 13 to case reports (3)

15 13 not 14 (998)

**Summary**

<b>Source</b>	<b>#Unique Refs</b>	<b>#Retained Refs</b>
Old bibliography	92	34
Literature Search(es)	1110	89
Author Added	1	0
Supporting Docs	1	1
Total		124

References from the literature search that were not retained had a poor study design, were not relevant to the topic, or had unclear or biased results.